Study of TX002100 for hereditary hemorrhagic telangiectasia needing iron or transfusions
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation clinical trials.
This trial tests an investigational drug, TX002100, for people with hereditary hemorrhagic telangiectasia (HHT) who need regular intravenous iron infusions or blood transfusions to manage bleeding. The goal is to see if it reduces the need for these supportive treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult with HHT.
- You need regular iron infusions or blood transfusions for HHT-related bleeding.
- If you can become pregnant (or have a partner who can), you must agree to use effective contraception during the study.
- You have not had major surgery in the last 4 weeks and do not plan any during the study.
- You have not had any vaccinations within 2 weeks before starting the study.
- You do not have other causes of anemia or other inherited bleeding disorders besides HHT.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ATV-1601 in people with HHT, a genetic condition that causes abnormal bleeding and blood vessel problems. The drug aims to reduce bleeding and anemia caused by HHT.
This trial tests a new topical gel (TOR-582) applied inside the nose to reduce nosebleeds in people with HHT. It may help by targeting the abnormal blood vessels that cause frequent bleeding.
This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.
This study looks at how iron supplements affect the immune system in people with HHT (a genetic condition that causes bleeding from abnormal blood vessels). You may be placed in one of three groups depending on your iron and ferritin levels.
This trial tests an experimental pill, engasertib, to reduce frequent nosebleeds in adults with a rare blood vessel condition called hereditary hemorrhagic telangiectasia (HHT). Participation may help if you have moderate to severe nosebleeds and need iron or blood transfusions.
This trial tests whether nintedanib can reduce how often and how severe nosebleeds are in adults with hereditary hemorrhagic telangiectasia (HHT). It may help by calming blood-vessel problems that cause bleeding.
Hear when a new Hereditary Hemorrhagic Telangiectasia (HHT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.